Abstract

CD109 involves in human cancers, but its role and mechanism in the chemosensitivity of nasopharyngeal carcinoma (NPC) cells is yet to be investigated. Our investigation discovered that the CD109 had abnormally higher expression in the NPC tissues and cells. By depleting or supplementing CD109 in the NPC cells, the aggressive capabilities of NPC cells were suppressed or augmented, respectively. Moreover, silencing of CD109 promoted NPC cells chemosensitivity to 5-FU, and also inhibited 5-FU-mediated cell biological behaviors, facilitating cell apoptosis. Furthermore, CD109 was found to regulate the activities of AKT/mTOR signaling in the NPC cells. The tumor-promotive effect of CD109 overexpression was partially annulled by AKT/mTOR signaling inhibition. Finally, we also observed that tumor growth was retarded in the xenograft mice model and activity of AKT/mTOR signaling was reduced in the CD109 deficient group. Our data indicated that CD109, could be a therapeutic biomarker candidate in NPC treatment.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.